It has been hypothesized that pharmacodynamic mechanisms reducing EGFR-TKI delivery to the target sites might constitute an important source of the variability of treatment responses among patients with NSCLC [5,18]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.